Dr. Craig H. Moskowitz, MD

Expert Publications

• High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis.
• Upfront transplantation for poor-risk aggressive non-Hodgkin lymphoma and Hodgkin's disease: who benefits?
• Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.
• Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma.
• Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma.
• Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
• Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999.
• Mantle cell lymphomas.
• Pretreatment prognostic factors and outcome in patients with relapsed or primary-refractory diffuse large B-cell lymphoma treated with second-line chemotherapy and autologous stem cell transplantation.
• Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma.
• Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma.
• CD5 negative, Cyclin D1-positive diffuse large B-cell lymphoma (DLBCL) presenting as ruptured spleen.
• Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma.
• High dose chemoradiotherapy and ASCT may overcome the prognostic importance of biologic markers in relapsed/refractory Hodgkin lymphoma.
• Controversies in the treatment of lymphoma with autologous transplantation.

Media Releases

Get to know Hematologist-Oncologist Dr. Craig H. Moskowitz, who serves patients in Miami, Florida.

Dr. Moskowitz is an internationally recognized leader in lymphoma clinical research and treatment, specializing in the care of patients with Hodgkin lymphoma and non-Hodgkin lymphoma.

As the Physician-in-Chief of the Oncology Service Line at the University of Miami Sylvester Comprehensive Cancer Center, he is responsible for the development, implementation, and administration of high quality, value-based oncology care at the main campus and satellites. He works across departments to improve the multidisciplinary care of cancer patients. 

As the leader of the Site Disease Groups, Dr. Moskowitz collaborates with group directors to enhance the patient navigation system and fosters multidisciplinary participation in the development and piloting of clinical trials.

Teaching students, he serves as a Professor within the Department of Medicine, Division of Medicine at the University of Miami Leonard M. Miller School of Medicine.

In regards to his educational background, Dr. Moskowitz graduated with his Bachelor of Science degree from Brooklyn College in 1980. He then went on to earn his medical degree from the Wayne State University School of Medicine in 1988.

Furthering his training, he performed his residency in internal medicine at Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses) in 1992, and his fellowship in hematology and medical oncology at Memorial Sloan Kettering Cancer Center (MSKCC) in 1995.

Licensed to practice medicine in Florida and New York, the doctor is board-certified in medical oncology by the American Board of Internal Medicine (ABIM). The ABIM is a physician-led, non-profit, independent evaluation organization driven by doctors who want to achieve higher standards for better care in a rapidly changing world.

Practice-changing, Dr. Moskowitz’s research focuses on improving the outcomes of patients with poor-risk diffuse large B cell lymphoma (DLBCL) and Hodgkin lymphoma. It has led to changes in the international standard of care for lymphoma patients. 

One area of accomplishment has been to optimize high-dose therapy and autologous stem cell transplantation, as well as new agents, to improve “salvage” therapy for patients with disease that has returned or is not responding to standard therapy. His second area of accomplishment has been to develop strategies that optimize the treatment of newly diagnosed DLBCL patients, according to the likelihood of their disease recurring. These include designing risk-adapted therapies, based on risk factors present before treatment and also the results of imaging studies. 

Hematology is the branch of medicine concerned with the study of the cause, prognosis, treatment, and prevention of diseases related to blood. Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. A hematologist-oncologist is a physician who specializes in the diagnosis, treatment, or prevention of cancer, malignant blood diseases such as leukemia, lymphoma, and multiple myeloma, and blood disorders such as iron-deficiency anemia, clotting abnormalities, hemophilia, and sickle-cell disease.

Having been recognized for his research on a national level through multiple awards, Dr. Moskowitz has lectured worldwide on lymphoma and stem cell transplantation. In addition, he is a member of the research council at MSKCC, and on the steering committees for the bi-annual international lymphoma conference in Lugano and the international Hodgkin lymphoma conference in Cologne.

Recommended Articles

• Prostate Drugs May Not Increase the Risk of Fractures

  About 8 million men in the U.S. between the ages of 50-years-old and 79-years-old suffer from enlarged prostate glands. Drugs used to treat an enlarged prostate gland, also known as benign prostatic hyperplasia (BPH), are of two types: 5-alpha reductase inhibitors and alpha-blockers. In a study,...

• This 12-year-old Is an Anomaly in the Ovarian Cancer Community

  Ovarian cancer usually strikes women who are at least in their fifties; however, Olivia Parslow is only twelve years old and is fighting the disease with her life.Olivia's storyOlivia had gained nearly 40 pounds in only three weeks, so her family was very concerned. Not only was she gaining an...

• How Common is Testicular Cancer?

  Testicular cancer is a form of cancer which affects the male testes or sex glands encased within the scrotum, a loose sac of tissue that hangs freely below the penis. Germ cells are specialized cells lining several heavily coiled tubular structures within the testes that are responsible for...

• Ovarian Cancer Survivor Dedicates Herself to Helping Others

  July 11th, 2014 is a day LeToy Hannah will never forget. She had gone into surgery to remove a non-cancerous cyst on her ovary and came out with a stage 3C ovarian cancer diagnosis. Hannah was shocked; her mother had to make the call to do a complete hysterectomy to remove all visible cancer while...

• How to Spot Breast Cancer Charity Scams

  October marks another year of Breast Cancer Awareness Month. The event, which started as just a week-long endeavor in 1985, is a time for the public to come together to raise awareness and fundraise for the disease. When used properly, donated funds can go towards research organizations...

• Gluten Could Trigger Lymphoma in Patients Who Already have Celiac Disease

  Celiac disease is a disease of the immune system that is said to be triggered by gluten, the protein in wheat products. It affects a few million people in the U.S. each year. Most who are diagnosed will go on a gluten-free diet, as that is currently the only treatment doctors know of which leads to...